All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Optimizing Treatment Patterns in Relapsed or Refractory Differentiated Thyroid Cancer

June 21st 2023

A panel of head and neck cancer experts discussed the nuances of managing relapsed or refractory DTC with lenvatinib or sorafenib, as well as sequencing considerations with targeted therapies in the second-line setting and beyond for patients with relapsed or refractory disease.

Study Protocol Differences May Affect BTK Inhibitor Performance in R/R CLL

June 21st 2023

Patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib in the phase 3 RESONATE trial achieved a significantly longer median progression-free survival compared with those in the phase 3 ALPINE trial, as well as a higher yet nonsignificant 2-year PFS estimate vs those in the phase 3 ELEVATE-RR trial.

FDA Approves Talazoparib Plus Enzalutamide for HRR Gene–Altered mCRPC

June 20th 2023

The FDA has approved talazoparib (Talzenna) plus enzalutamide (Xtandi) for use in patients with homologous recombination repair gene–mutated metastatic castration-resistant prostate cancer.

Anbalcabtagene Autoleucel Generates Responses in Relapsed/Refractory LBCL

June 20th 2023

The novel, autologous, anti-CD19 CAR T-cell therapy anbalcabtagene autoleucel produced durable responses and was well tolerated in patients with relapsed/refractory large B-cell lymphoma.

Investigators to Explore Potential of LP-300 With Chemo in Never Smokers With Advanced Lung Cancer

June 20th 2023

Joshua Eric Reuss, MD, discusses the enrollment criteria for the HARMONIC trial, the demonstrated safety and efficacy of LP-300, and potential benefits of the agent for never smokers with advanced non–small cell lung cancer.

Pembrolizumab/Chemo Regimen Meets pCR End Point, But Misses EFS Goal in Resectable Gastric/GEJ Adenocarcinoma

June 20th 2023

Neoadjuvant treatment with pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab plus chemotherapy, then pembrolizumab monotherapy, led to a statistically significant improvement in pathological complete response rates vs neoadjuvant chemotherapy alone in patients with locally advanced, resectable gastric and gastroesophageal junction adenocarcinoma.

Breakthrough in Glioblastoma Treatment With the Help of a Virus

June 20th 2023

In a recently published manuscript, Howard Colman, MD, PhD, identified a potential breakthrough in glioblastoma treatment.

FDA Places Clinical Hold on BCMA-Directed Modified CAR T-Cell Therapy in Multiple Myeloma

June 20th 2023

The FDA has placed a hold on the clinical program for the investigational new drug CART-ddBCMA for the treatment of patients with relapsed/refractory multiple myeloma.

Strides in GI Cancer Subsets Influence Advances

June 20th 2023

Tanios S. Bekaii-Saab, MD, highlights the unmet needs in GI malignancies and discusses how interdisciplinary meetings, such as the 20th Annual Meeting of the International Society of Gastrointestinal Oncology, provide the framework for disseminating information and driving innovative advances.

Pazopanib Associated With Higher Wound Complication Rates in Non-rhabdomyosarcoma Soft Tissue Sarcoma

June 20th 2023

R. Lor Randall, MD, FACS, discusses the use of neoadjuvant pazopanib in patients with non-rhabdomyosarcoma soft tissue sarcoma, expanded on findings from the subgroup analysis of ARST1321, and detailed the implications of these findings.

Liso-Cel Elicits ORR of 97% in Relapsed/Refractory Follicular Lymphoma

June 19th 2023

A single administration of lisocabtagene maraleucel provided deep and durable remissions when used as third-line treatment in patients with relapsed or refractory follicular lymphoma, including those with high-risk features.

Liso-Cel Elicits Rapid, Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma

June 19th 2023

The CAR T-cell therapy lisocabtagene maraleucel produced rapid and durable responses in heavily pretreated patients with relapsed/refractory mantle cell lymphoma.

Ibrutinib Plus Chemoimmunotherapy Fails to Improve PFS in Pretreated Follicular Lymphoma, MZL

June 19th 2023

The addition of ibrutinib to bendamustine plus rituximab or R-CHOP did not lead to a statistically significant improvement in progression-free survival vs either chemoimmunotherapy regimen alone in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma.

DESTINY-CRC02 Trial Continues to Support the Use of T-DXd in HER2+ Metastatic CRC

June 19th 2023

Kanwal Pratap Singh Raghav MBBS, MD, discusses data from DESTINY-CRC01 that supported the DESTINY-CRC02 trial, key efficacy and safety data from the trial, and the importance of identifying patients with HER2-positive CRC who may benefit from ADCs like T-DXd in clinical practice.

Ibrutinib, Obinutuzumab, Venetoclax Triplet Elicits Sustained Clinical Benefit in Mantle Cell Lymphoma

June 19th 2023

The combination of ibrutinib, obinutuzumab, and venetoclax was associated with prolonged survival in patients with newly diagnosed or relapsed/refractory mantle cell lymphoma.

New Study Suggests Simple Test Could Detect Breast and Ovarian Cancer Risk Without Genetic Sequencing

June 19th 2023

Researchers from Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Medical University of Lodz have found a way to detect increased cancer risk associated with BRCA1 and BRCA2 mutations without genetic sequencing, according to a new study in Nature Communications.

Determining the Optimal Use of Adjuvant Immunotherapy in Renal Cell Carcinoma

June 19th 2023

Kidney and renal pelvis cancers are one of the 10 most common new malignant diagnoses in both men and women in the United States, with an estimated 52,360 new cases in men and 29,440 new cases in women per year.

Tirabrutinib Aims to Fill Gap in the PCNSL Treatment Landscape

June 19th 2023

Lakshmi Nayak, MD, discusses the treatment landscape for patients with primary central nervous system lymphoma and how tirabrutinib may serve as an option for those with relapsed/refractory disease.

Obe-Cel Demonstrates Durable, Safe Responses in Relapsed/Refractory B-ALL

June 18th 2023

Claire Roddie, MD, discusses the rationale for investigating obecabtagene autoleucel in patients with relapsed/refractory B-cell acute lymphoblastic leukemia, details the key topline findings from the FELIX trial, and provides insights on unmet needs that remain for this patient population.

Novel Methylome Enrichment Platform Shows Promise Detecting Early-Stage and Low DNA-Shedding Solid Tumors

June 17th 2023

Michael Shusterman, MD, expands on the need for accurate early detection methods in solid tumors for which there aren’t proper surveillance tests, advantages of the unique methylation sequencing technique harnessed by this novel assay, and more.